Abstract
Anti‐spike antibody testing has emerged as a powerful tool to assess SARS‐CoV‐2 vaccine response in solid organ transplant (SOT) recipients, many of whom remain at risk for COVID‐19 despite vaccination. Neither the US Food and Drug Administration nor major transplant societies recommend testing antibody responses after vaccination, or its general incorporation into COVID‐19 risk stratification. Notably, in December 2021, the American Society of Transplantation recognized anti‐spike seronegativity as a consideration for use of monoclonal antibody pre‐exposure prophylaxis. In this viewpoint, we narrate the evolving rationale for anti‐spike antibody testing and ultimately recommend that all SOT recipients be tested for anti‐spike antibody after vaccination. This result should then be used to personalize efforts to improve protection versus COVID‐19 for the most vulnerable, such as additional vaccination strategies and consideration of passive immunoprophylaxis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
